Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

Standard

Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. / Erttmann, Rudolf; Bielack, S; Landbeck, G.

In: CANCER CHEMOTH PHARM, Vol. 15, No. 2, 2, 1985, p. 101-104.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{95b68ea3588e41a58e697213599ace37,
title = "Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.",
abstract = "Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.",
author = "Rudolf Erttmann and S Bielack and G Landbeck",
year = "1985",
language = "Deutsch",
volume = "15",
pages = "101--104",
journal = "CANCER CHEMOTH PHARM",
issn = "0344-5704",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

AU - Erttmann, Rudolf

AU - Bielack, S

AU - Landbeck, G

PY - 1985

Y1 - 1985

N2 - Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.

AB - Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.

M3 - SCORING: Zeitschriftenaufsatz

VL - 15

SP - 101

EP - 104

JO - CANCER CHEMOTH PHARM

JF - CANCER CHEMOTH PHARM

SN - 0344-5704

IS - 2

M1 - 2

ER -